Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Canton (CC) pulls back from highs as bulls struggle below $0.17

Canton (CC) pulls back from highs as bulls struggle below $0.17

CryptoNewsNetCryptoNewsNet2026/05/27 00:18
By:CryptoNewsNet
Back to the list

Canton (CC) pulls back from highs as bulls struggle below $0.17

Canton (CC) pulls back from highs as bulls struggle below $0.17 image 0  invezz.com 29 m
Canton (CC) pulls back from highs as bulls struggle below $0.17 image 1
(CC) fell to around $0.16 on Tuesday as sellers pushed the token lower from intraday highs, renewing questions about whether bulls can maintain the recent rally.

The move marked a 3.4% decline over the past 24 hours and followed a week of gains driven by network-related developments and new exchange listings that briefly brought the token back into focus for investors.

Canton pares recent gains

Canton has pulled back from intraday highs as traders lock in profits and short-term momentum begins to fade.

The token is lower over the past 24 hours, underperforming several altcoins, including Render, NEAR Protocol, and Worldcoin.

Although the decline has been relatively modest, bulls continue to struggle to break above the $0.17 level in an attempt to push toward a new all-time high.

CC remains roughly 17% below its record peak reached in early February.

Recent gains had been supported by optimism around developments within the Canton Network ecosystem.

Over the past week, sentiment improved after Helios Finance announced plans to launch what it describes as the first credit card native to the Canton Network.

The Visa-powered “Helios Reserve Card” is expected to allow users to borrow against their CC holdings and spend funds at more than 150 million merchants globally.

CC also gained as the crypto exchange Gate listed USDCx, the native stablecoin of the Canton Network.

Despite the pullback, the decline is relatively minor and leaves CC about 8% higher on the week.

Canton price forecast: what’s next?

The technical picture for CC is mixed but leans cautiously bullish if support holds.

A key factor is that Canton is holding above a horizontal support zone amid a declining daily volume.

The daily chart also shows the 50-day and 100-day simple moving averages converging, with a potential golden cross forming if the 50 SMA crosses above the 100 SMA.

That configuration signals improving medium-term momentum for buyers.

Canton (CC) pulls back from highs as bulls struggle below $0.17 image 2 Canton price chart.

Meanwhile, the relative strength index (RSI) is downsloping from recent highs but remains above the 50 midpoint.

This indicates that bulls retain some control even as momentum cools.

Immediate resistance lies around $0.17; a decisive break and daily close above that level would open the path toward the previous all-time high near $0.20.

Dynamic support from moving averages sits slightly below current prices.

On the flipside, if the RSI dips below 50, it would suggest a deeper pullback.

Buyers will have to defend the $0.15 support zone to maintain the probability of retesting the all-time peak.

A sustained breakdown below $0.15 could invite further downside pressure, with $0.13 a key bearish target.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Safe Haven Amid AI Crash! Major Pharmaceutical Stocks Approach Historic Highs

Amid concerns over AI capital expenditures, funds are seeking a "certainty premium." State Street Healthcare ETF reached a record high. Eli Lilly and AbbVie are both approaching their historical highest closing prices, while Gilead and Amgen have surged 7.7% and 7.2% respectively over the past five days. Eli Lilly continues to bet on the future through its GLP-1 dominance and 40 M&A deals totaling $20 billion. AbbVie's core drug Skyrizi has shown positive data for its new subcutaneous formulation, which is expected to extend its patent and drive additional sales.

华尔街见闻•2026/10/16 00:37
Safe Haven Amid AI Crash! Major Pharmaceutical Stocks Approach Historic Highs

Fed Officials Turn Hawkish: Daly Says Supply Shocks Should No Longer Be "Wait-and-See," Hammack Suggests More Aggressive Rate Hikes May Be Needed if Inflation Expectations Become Entrenched

San Francisco Fed President Daly stated that the traditional "wait and see" approach to supply-side shocks has been abandoned, noting that businesses in her district are tending to pass rising costs on to consumers and that current inflation risks are "skewed fully to the upside." Cleveland Fed President Hammack said that once the public forms an "inflationary mindset," the difficulty of monetary policy regulation will increase significantly, and the required interest rate hikes will then exceed expectations.

华尔街见闻•2026/10/16 00:11
Fed Officials Turn Hawkish: Daly Says Supply Shocks Should No Longer Be "Wait-and-See," Hammack Suggests More Aggressive Rate Hikes May Be Needed if Inflation Expectations Become Entrenched

Over $10 billion in market value evaporated in four trading days as CoreWeave (CRWV.US) debt risks trigger sell-off, but Deutsche Bank sees it as a buying opportunity

Deutsche Bank believes that the recent sell-off of CoreWeave lacks sufficient company fundamentals to justify it, and the sharp price correction has instead created a buying opportunity for investors.

智通财经•2026/10/15 22:37
Over $10 billion in market value evaporated in four trading days as CoreWeave (CRWV.US) debt risks trigger sell-off, but Deutsche Bank sees it as a buying opportunity